�� IMAGE PLACEHOLDER: Hero Image: A hematologist reviewing blood cell analysis results on a large monitor in a clinical laboratory setting, with patients visible in the background infusion suite. Caption: Hematology Billing Services — Expert Revenue Cycle Management for Blood Disorder & Hematologic Malignancy Practices.
Hematology is a specialty where the science is complex, the stakes are high, and the billing, if done incorrectly, costs your medical practice far more than most you realize. Whether your practice manages iron deficiency anemia, sickle cell disease, myelodysplastic syndromes, clotting disorders, or hematologic malignancies like leukemia and lymphoma, every patient encounter carries a dense web of CPT codes, ICD-10 diagnoses, HCPCS drug codes, infusion timing requirements, and prior authorization obligations.
We have written this guide for US hematologists, hematology-oncology physicians, practice managers, and administrators who want a clear, authoritative, and immediately actionable resource on hematology billing services.
And at the end, we will show you why House of Outsourcing is the trusted billing partner that hematology practices across the United States turn to when they need results.
Hematology medical billing sits at the intersection of diagnostic medicine, procedural care, and high-cost drug administration, and each of those three areas comes with its own set of coding rules, payer requirements, and compliance obligations. No other non-surgical specialty demands the same breadth of coding expertise in a single practice setting.
Here are the key factors that makes our hematology billing services a genuine specialty within medical billing:
As an experienced healthcare professional you know that in hematology, the ICD-10-CM diagnosis code is not a formality, it is the clinical justification that determines whether payers will authorize and reimburse every procedure, drug, and service your practice provides. Using unspecified or incorrect diagnosis codes in hematology billing is one of the leading causes of medical necessity denials.
| ICD-10 Range | Category | Examples in Hematology Practice |
|---|---|---|
| D50–D53 | Nutritional Anemias | D50.0 Iron deficiency anemia due to blood loss (chronic); D52.0 Dietary folate deficiency anemia; D53.9 Unspecified nutritional anemia |
| D55–D58 | Hemolytic Anemias | D57.1 Sickle-cell disease without crisis; D57.00 Hb-SS with crisis, unspecified; D58.0 Hereditary spherocytosis |
| D59 | Acquired Hemolytic Anemias | D59.0 Drug-induced autoimmune hemolytic anemia; D59.11 Warm antibody autoimmune hemolytic anemia (WAIHA) |
| D60–D64 | Aplastic & Other Anemias | D61.1 Drug-induced aplastic anemia; D61.3 Idiopathic aplastic anemia; D64.9 Anemia, unspecified |
| D65–D69 | Coagulation Defects | D66 Hereditary factor VIII deficiency (hemophilia A); D68.0 Von Willebrand disease; D68.311 Acquired hemophilia |
| D70–D77 | Other Blood Disorders | D70.0 Congenital agranulocytosis; D72.829 Lymphocytosis; D75.0 Familial erythrocytosis |
| D80–D89 | Immune Disorders | D83.9 Common variable immunodeficiency; D84.9 Immunodeficiency, unspecified; D89.810 GVHD |
| C81–C86 | Lymphomas | C81.90 Hodgkin lymphoma, unspecified; C83.30 Diffuse large B-cell lymphoma; C85.90 Non-Hodgkin lymphoma, unspecified |
| C91–C95 | Leukemias | C91.00 Acute lymphoblastic leukemia; C92.00 Acute myeloid leukemia; C95.90 Leukemia, unspecified |
| C88–C90 | Plasma Cell Neoplasms | C90.00 Multiple myeloma, not in remission; C90.10 Plasma cell leukemia; C88.2 Heavy chain disease |
| D46 | Myelodysplastic Syndromes | D46.0 Refractory anemia without RS; D46.20 Refractory anemia with excess blasts; D46.9 MDS, unspecified |
| D47 | Neoplasms of Uncertain Behavior | D47.1 Chronic myeloproliferative disease; D47.3 Essential thrombocythemia; D47.4 Osteomyelofibrosis |
�� Tip: Code to the Highest Specificity Available in Hematology
Hematology diagnosis codes demand the highest possible specificity. For example, sickle cell disease has dozens of ICD-10 sub-codes based on genotype (Hb-SS, Hb-SC, sickle-beta thalassemia) and crisis type (with crisis, without crisis, with acute chest syndrome). Payers use these distinctions to determine medical necessity for high-cost treatments like hydroxyurea, voxelotor, or crizanlizumab infusions. Using D57.1 (‘Sickle-cell disease without crisis’) when the patient is in crisis (D57.00) is both clinically inaccurate and a compliance risk. Always code from the clinical documentation — not the superbill checkbox.
CPT code selection in hematology billing covers three main categories: procedural codes for bone marrow and other hematologic procedures, infusion and administration codes, and evaluation and management codes. Each category has its own coding rules and documentation requirements.
Bone marrow aspiration and biopsy are among the highest-volume and highest-value procedures in hematology. Correct coding depends on what was performed, aspiration alone, biopsy alone, or both, and whether the physician also interpreted the specimen.
| CPT Code | Procedure Description | Critical Billing Notes |
|---|---|---|
| 38220 | Bone marrow aspiration | Aspiration alone; document site (iliac crest, sternum), technique, and yield |
| 38221 | Bone marrow biopsy, needle or trocar | Biopsy alone (core biopsy); document site and number of cores obtained |
| 38222 | Bone marrow biopsy and aspiration | Both performed; bill 38222 rather than 38220 + 38221 when both done at same session |
| 38230 | Bone marrow harvesting for transplant — allogeneic | Document donor type, collection volume, and transplant indication |
| 38232 | Bone marrow harvesting for transplant — autologous | Document autologous collection; often requires separate facility billing |
| 38240 | Hematopoietic progenitor cell (HPC) transplant — allogeneic | High-cost procedure; requires PA and transplant center documentation |
| 38241 | HPC transplant — autologous | Document mobilization, collection, and infusion dates separately |
| 38242 | Allogeneic lymphocyte infusions | Document donor, lymphocyte dose (cells/kg), and clinical indication |
| 85097 | Bone marrow interpretation and report | Professional component — bill when physician interprets BM specimen |
| 88182 | Flow cytometry, each cell surface marker (technical) | Bill per marker analyzed; professional interpretation billed separately |
| 88184 | Flow cytometry, first marker — professional | Professional component of flow cytometry interpretation |
�� Tip: Bill 38222 — Not 38220 + 38221 — When Both Are Performed
When a physician performs both a bone marrow aspiration and a needle biopsy at the same session, the correct code is 38222 — not a combination of 38220 and 38221. Billing 38220 and 38221 separately when 38222 applies is a CCI bundling violation. However, if the aspiration and biopsy are performed at different anatomical sites during the same session, separate billing may be appropriate with modifier -59 or -XS and thorough documentation.
| CPT Code | Test Description | Billing Note |
|---|---|---|
| 85025 | Complete Blood Count (CBC) with automated differential | Most common hematology lab; document clinical indication |
| 85027 | CBC without automated differential | Use 85027 only when differential not performed or ordered |
| 85610 | Prothrombin time (PT) | Coagulation monitoring; frequent in anticoagulation management |
| 85730 | Partial thromboplastin time (PTT/APTT) | Key coagulation test; document indication (monitoring vs. diagnosis) |
| 85651 | Erythrocyte sedimentation rate (ESR), non-automated | Inflammation marker; code 85652 for automated method |
| 83615 | Lactate dehydrogenase (LDH) | Elevated in hemolysis, lymphoma, and leukemia — document clinical context |
| 86367 | Stem cell enumeration — each antibody | CD34+ cell counting for transplant planning |
| 86355 | B cells, total count | Lymphocyte subset panel — document immunodeficiency or malignancy indication |
| 86356 | MHC class II antigen testing | HLA typing for transplant compatibility — requires separate PA |
| 81219 | CALR (calreticulin) gene analysis | Molecular test for myeloproliferative neoplasms |
| 81270 | JAK2 gene analysis (V617F variant) | Essential for polycythemia vera diagnosis; document testing indication |
| 81245 | FLT3 gene analysis | AML molecular testing; required for targeted therapy selection |
| CPT Code | Visit Type | MDM Complexity | Common Hematology Use |
|---|---|---|---|
| 99213 | Established patient — office | Low | Routine CBC follow-up, simple anemia monitoring |
| 99214 | Established patient — office | Moderate | Chronic ITP management, anticoagulation follow-up |
| 99215 | Established patient — office | High | Complex MDS, leukemia management, multiple medications |
| 99204 | New patient — office | Moderate | New referral for anemia workup or clotting disorder |
| 99205 | New patient — office | High | Complex new patient: MDS, lymphoma, hemophilia |
| 99221-99223 | Initial hospital care | Low/Mod/High | Inpatient admission for hematologic emergency or transplant |
| 99231-99233 | Subsequent hospital care | Low/Mod/High | Daily inpatient management during transplant or acute leukemia |
�� IMAGE PLACEHOLDER: Image 1: A professional infographic showing the three major CPT code categories in Hematology — Bone Marrow Procedures, Laboratory/Diagnostics, and Infusion Administration — in a visual hierarchy with color coding. Caption: Hematology Billing Services — The Three CPT Code Pillars Every Hematology Practice Must Master.
For most hematology practices, infusion billing represents the largest single component of revenue, and the highest-risk area for billing errors, denials, and compliance investigations. High-cost biologic therapies, blood factors, and supportive medications administered in your infusion suite carry reimbursements that dwarf most office-based services, which is exactly why payers scrutinize every unit billed.
Infusion administration codes are time-based and hierarchical. They must be billed in a specific order, with start and stop times documented for every drug and every infusion session. There is no flexibility here missing time documentation means a non-compliant claim.
| CPT Code | Administration Description | Key Hematology Billing Rule |
|---|---|---|
| 96413 | Chemotherapy infusion — initial, up to 1 hour | Use for antineoplastic agents; document drug name, dose, route, start/stop times |
| 96415 | Chemotherapy infusion — each additional hour | Add-on to 96413; bill per additional hour; must document extended time |
| 96401 | Chemotherapy injection — non-infusion, non-hormonal | Subcutaneous or intramuscular; not time-based; document route and drug |
| 96402 | Hormonal antineoplastic agent injection | Leuprolide, degarelix, fulvestrant; document drug, dose, and indication |
| 96365 | Non-chemo therapeutic infusion — initial, up to 1 hour | Immunoglobulin (IVIG), iron infusion, zoledronic acid, rituximab (non-chemo use) |
| 96366 | Non-chemo therapeutic infusion — each additional hour | Add-on; time-based; document extended infusion time |
| 96367 | Therapeutic infusion — additional sequential drug | Second drug, infused sequentially; document sequence and time |
| 96368 | Therapeutic infusion — concurrent | Same IV line, concurrent with primary infusion; limited to once per encounter |
| 96360 | Hydration infusion — initial, 31 min to 1 hour | Pre- or post-chemo hydration; cannot be reported alone if only hydration |
| 96361 | Hydration infusion — each additional hour | Add-on; document medical necessity for extended hydration |
| 96372 | Therapeutic, prophylactic or diagnostic injection — SC or IM | Non-antineoplastic SC/IM injections; includes epo-stimulating agents, G-CSF |
J-codes are HCPCS Level II codes used to bill for the actual drugs administered in your hematology practice. In a specialty where a single infusion of a biologic agent can cost $15,000 to $50,000 or more, J-code accuracy is not a coding exercise, it is a financial imperative.
| J-Code | Drug / Agent | Critical Billing Notes |
|---|---|---|
| J0881 | Darbepoetin alfa (Aranesp) — 1 mcg | Report actual mcg administered; NOT dose ordered. PA required for non-dialysis patients |
| J0885 | Epoetin alfa (Epogen/Procrit) — 1000 units | Report actual units given; round to nearest 100 units administered |
| J0897 | Denosumab (Xgeva) — 1 mg | Used in multiple myeloma bone protection; document oncology indication |
| J9034 | Bendamustine HCl (Treanda) — 1 mg | Chemotherapy; document dose in mg/m2 and total mg administered |
| J9055 | Bortezomib (Velcade) — 0.1 mg | Multiple myeloma; SC injection; document BSA-based dosing |
| J9145 | Daratumumab (Darzalex) — 10 mg | Myeloma biologic; very high cost; always verify PA before administration |
| J9229 | Ibrutinib (Imbruvica) — 140 mg | Oral oncolytic — billed per actual capsule dispensed; Medicare Part D consideration |
| J9306 | Rituximab (Rituxan) — 100 mg | Lymphoma and autoimmune; bill per 100 mg units; PA required |
| J1459 | IVIG — immune globulin, 500 mg | Used in ITP, AIHA, CIDP; PA required; bill actual grams administered |
| J0897 | Factor VIII (antihemophilic) — 1 IU | Hemophilia A; extremely high cost; units billed must match infusion record exactly |
| J7195 | Factor IX complex — 1 IU | Hemophilia B; document IU administered; PA required from all payers |
| J0217 | Atezolizumab (Tecentriq) — 10 mg | Immunotherapy; document indication (hematologic vs. solid tumor) |
| Q2049 | Infliximab biosimilar — per 10 mg | Biosimilar of Remicade; ensure correct biosimilar J-code — do not use J1745 if biosimilar dispensed |
�� Biosimilar Billing Alert
Biosimilar drugs have their own separate J-codes that are different from the reference biologic J-code. Billing J9306 (Rituximab-Rituxan) when you actually administered a rituximab biosimilar (e.g., Ruxience – Q5119 or Truxima – Q5115) is a J-code error that can result in claim denial, incorrect reimbursement, and audit exposure. As biosimilars become standard of care in hematology, keeping your J-code formulary current is a monthly responsibility — not an annual one. Review HCPCS biosimilar code updates quarterly.
Blood transfusions are a high-frequency procedure in hematology practices, particularly for patients with aplastic anemia, MDS, sickle cell disease, and chemotherapy-induced anemia. Transfusion billing involves both the administration codes and, in some settings, the blood product codes themselves.
| CPT Code | Transfusion Service | Billing Notes |
|---|---|---|
| 36430 | Transfusion, blood or blood components | Base transfusion administration code; document product type, volume, and clinical indication |
| 36440 | Push transfusion, blood, 2 years or under | Pediatric transfusion; document patient age and weight |
| 36450 | Exchange transfusion, newborn | Neonatal; highly specific — document as exchange vs. simple transfusion |
| 36455 | Exchange transfusion, other than newborn | Adult exchange; common in sickle cell disease (automated exchange) |
| 86950 | Leukocyte transfusion | Granulocyte transfusion; document donor, product, and irradiation status |
| 86960 | Volume reduction of blood or blood product | Document processing details; often performed for neonatal or pediatric patients |
| P9010 | Blood (whole) — per unit | Blood product HCPCS code; hospital/facility typically bills product codes; verify payer rules |
| P9016 | Red blood cells (RBCs) — per unit | Packed RBCs; document irradiated, leukoreduced, CMV-negative status as applicable |
| P9019 | Platelets — each unit | Platelet transfusion; document pool vs. single donor platelets |
| P9017 | Fresh frozen plasma (FFP) — donor retested | Document coagulation deficiency indication; verify patient consent and adverse reaction monitoring |
�� Tip: Transfusion Adverse Reaction Documentation Protects Your Claim
Payers in the USA increasingly require documentation that transfusion adverse reactions were monitored and managed. In addition to the product and administration documentation, your infusion nursing notes should capture pre-transfusion vital signs, monitoring during transfusion (at 15-minute intervals), and post-transfusion vital signs. This documentation not only protects patient safety — it protects your claim from medical necessity challenges and supports any additional E/M codes billed on transfusion encounter days.
In hematology, prior authorization is not an occasional administrative task, it is a constant, high-stakes workflow that governs access to some of the most expensive medications in medicine. A missed PA for a biologic infusion costing $20,000 is not just a billing problem; it is potentially a $20,000 write-off with no recourse to bill the patient.
| Hematology Service / Drug | Medicare FFS | Commercial / Medicare Advantage |
|---|---|---|
| IVIG (immune globulin infusion) | LCD applies — clinical criteria required | Almost always PA required |
| Erythropoiesis-stimulating agents (ESAs) | PA required — strict criteria | PA required; step therapy often required |
| Rituximab for hematologic conditions | PA required | Always required |
| Daratumumab (Darzalex) for myeloma | PA required | Always required |
| Blood factor concentrates (hemophilia) | PA required; high-cost review | Always required; quantity limits enforced |
| CAR T-cell therapy | PA required; site-of-care review | Always required; significant payer review |
| Bone marrow / stem cell transplant | PA required; transplant center criteria | Always required; committee review |
| Oral oncolytics (ibrutinib, venetoclax) | Part D coverage — formulary PA | Always required; step therapy common |
| Hydroxyurea for sickle cell disease | Generally no PA (Medicare FFS) | Often PA required — document SCD diagnosis |
| Genetic/molecular testing (NGS panels) | LCD applies — diagnosis-specific criteria | PA or prior notification required by most plans |
| Bone marrow aspiration and biopsy | No PA (Medicare FFS) | PA often required for elective biopsies |
In hematology, documentation is the foundation of every claim, and the shield that protects your practice in the event of an audit. Complex diagnoses, high-cost drug administrations, and expensive procedures like bone marrow biopsies all attract payer scrutiny. Your documentation must leave no room for doubt.
ℹ️ Documentation for Erythropoiesis-Stimulating Agents (ESAs) — CMS Requirements
CMS has specific Local Coverage Determinations (LCDs) governing ESA use (darbepoetin, epoetin alfa) in hematology patients. Documentation must establish: the specific anemia diagnosis (with ICD-10 code), the hemoglobin/hematocrit level at the time of initiation (must be below CMS threshold), the patient is not iron-deficient before initiation, and the target hemoglobin does not exceed CMS limits. Billing ESAs without this documentation is one of the top compliance risks in hematology and a frequent OIG audit target. Source: cms.gov/medicare-coverage-database (search ESA LCD)
Medicare is the dominant payer for many hematology practices, especially those serving older adults with myeloid malignancies, MDS, and age-related blood disorders. Medicare’s billing rules for hematology are among the most detailed and most frequently audited in all of medicine.
According to our experience the prior authorization (PA) is one of the most important and most time-consuming administrative responsibilities in general surgery billing services. For elective procedures, operating without a valid prior authorization from the payer is virtually guaranteed to result in a zero-payment denial.
| General Surgery Procedure | Medicare Fee-for-Service | Commercial / Medicare Advantage |
|---|---|---|
| Laparoscopic cholecystectomy (elective) | Generally no PA | Almost always requires PA |
| Emergency cholecystectomy | No PA required | Usually exempt if documented emergency |
| Elective hernia repair | No PA (Medicare FFS) | Commonly requires PA |
| Bowel resection (elective) | No PA (Medicare FFS) | Almost always requires PA |
| Bariatric surgery (sleeve/bypass) | CMS requires clinical criteria | Always requires PA + committee review |
| Thyroid and parathyroid surgery | No PA (Medicare FFS) | Usually requires PA |
| Mastectomy for cancer | No PA (Medicare FFS) | Usually requires PA |
| Breast reconstruction post-mastectomy | No PA (Medicare FFS; WHCRA applies) | Typically requires PA |
| Adrenalectomy | No PA (Medicare FFS) | PA required in most plans |
| Soft tissue tumor excision > 3 cm | No PA (Medicare FFS) | Commonly requires PA |
�� Tip: Get Authorization for the Anticipated Procedure AND Possible Complications
A common problem in general surgery billing: you get PA for a laparoscopic cholecystectomy (47562) but the case converts to open (47600), or you find an unexpected common bile duct stone requiring ERCP. The PA you obtained does not cover these additional procedures. Train your pre-authorization team to request broader authorization language that covers likely related procedures, conversion to open, intraoperative cholangiography (CPT 47563), and possible bile duct exploration. Document all authorization confirmations by number and date in the operative scheduling record.
Medicare and Medicaid are major payers for general surgery practices, particularly for older adult patients presenting with gallbladder disease, hernia, colorectal conditions, and cancer. Each program has specific billing rules that surgical practices must follow.
You know that denial management in general surgery billing is not a passive activity, it is an active revenue protection strategy. Every denied claim is recoverable revenue. But only if your team identifies the root cause quickly and appeals within the payer’s filing window.
| Denial Reason | Denial Code | Root Cause in General Surgery | Corrective Action |
|---|---|---|---|
| Missing Prior Authorization | CO-15 | Elective procedure performed without PA or PA number omitted from claim | Implement PA tracking system; include auth number on every elective surgical claim |
| Global Period Bundling | CO-97 | Post-op service billed without correct modifier during global period | Train staff on global periods; apply -24, -58, -78, or -79 modifier as appropriate |
| Wrong Approach Code | CO-11 | Open code billed for laparoscopic procedure (or vice versa) | Implement operative note vs. code audit at charge entry; coder must review op note |
| Medical Necessity Denied | CO-50 | ICD-10 code does not support CPT procedure code | Use most specific ICD-10; link post-op diagnosis to procedure — not pre-op |
| Modifier Missing or Wrong | CO-4 | Bilateral procedure without -50; multiple procedures without -51 | Implement modifier checklist at charge capture; audit claims pre-submission |
| NCCI Bundling Conflict | CO-97 | Two procedures submitted that are bundled per NCCI edits | Run NCCI check before submission; apply -59 or X-modifier with documentation |
| Assistant Surgeon Not Covered | CO-5 | Medicare does not cover assistant surgeon for this procedure | Verify Medicare assistant surgeon approval for CPT code before surgery |
| Timely Filing Exceeded | CO-29 | Claim not submitted within payer's filing window | Implement claim submission monitoring; submit within 48-72 hours of service |
| Patient Ineligible | CO-27 | Insurance terminated or patient not covered on date of service | Verify eligibility day-of-service for all scheduled surgical cases |
�� Tip: Build a 72-Hour Claim Submission Rule for Surgery
In general surgery billing, every day a claim sits unsubmitted after an operative case is a day you are not getting paid. Implement a firm practice policy: all surgical claims must be coded, scrubbed, and submitted within 72 hours of the procedure.
General surgeons are not only billing for operative procedures in the USA, but they also bill for office-based Evaluation and Management (E/M) services, pre-operative consultations, post-discharge follow-up, and hospital visits. Each has its own billing rules within the context of the global surgical package.
| E/M Scenario | Modifier Required | Billing Rule |
|---|---|---|
| Office visit — decision for major surgery, same day as surgery | Modifier -57 | Required to unbundle from 90-day global; bill the E/M + -57 |
| Office visit — decision for minor surgery (0/10-day global) | Modifier -25 | Required to bill E/M same day as procedure |
| Post-op visit — unrelated condition during global period | Modifier -24 | Document clearly that condition is unrelated to surgery |
| Hospital visit during global period — unrelated | Modifier -24 | E/M for conditions unrelated to surgery are separately billable |
| Transfer of post-op care | Modifiers -54/-55 | Primary surgeon bills -54; receiving physician bills -55 |
| New patient consult (office) | 99202-99205 | No longer separately payable by Medicare; use standard E/M codes |
| Hospital admission (inpatient initial) | 99221-99223 | Bill when admitting the patient; document MDM level |
| Subsequent hospital visit during global | Included in global package | Do NOT bill separately for routine post-op hospital visits |
Measuring the right metrics is what separates a well-managed general surgery revenue cycle from one that is constantly reactive. These are the KPIs that define high-performing general surgery medical billing services.
| KPI Metric | General Surgery Benchmark | What It Measures |
|---|---|---|
| Clean Claim Rate | > 95% | % of surgical claims accepted without error on first submission |
| Denial Rate | < 5% | % of claims denied; 7-12% without active management in general surgery |
| Days in A/R | < 35 days | Average time from surgery to payment — longer = workflow problem |
| Net Collection Rate | > 96% | % of collectible surgical revenue actually collected |
| A/R > 90 Days | < 10% of total A/R | Aging surgical A/R signals systemic denial or follow-up gaps |
| Claim Submission Lag | < 72 hours | Days between surgery date and claim submission |
| Authorization Denial Rate | < 2% | PA-related denials — should be near zero with proper workflow |
| Modifier Error Rate | < 1% of surgical claims | Modifier errors — tracked via denial CO-4; signals coder training gap |
| Cost to Collect | 5-9% of collections | Total billing cost as % of surgical revenue collected |
| First-Pass Resolution Rate | > 90% | % of denied claims resolved without second-level appeal |
Keeping up with annual CPT and fee schedule changes is a revenue protection strategy in general surgery. Here is what you need to know for 2026.
The global surgical package includes the pre-operative evaluation on the day of surgery (and one day before for major procedures), the intraoperative services, all routine post-operative care within the global period, and complications that do not require a return to the OR. Separate services, unrelated conditions, return-to-OR complications, diagnostic tests, and staged procedures — can be billed separately with the correct modifier.
Use modifier -24 for unrelated E/M services during the global period; -58 for planned staged procedures returning to the OR; -78 for unplanned returns to the OR for complications related to the original surgery; and -79 for unrelated procedures performed during the global period. Using the wrong modifier or no modifier results in bundling denials.
Bill only the open procedure code (since that is what was ultimately performed). Do not bill both the laparoscopic and open codes. Document the conversion clearly in the operative note and consider modifier -22 (Increased Procedural Services) if the conversion significantly increased complexity and operative time, with full supporting documentation attached.
Yes. House of Outsourcing provides general surgery billing services for professional (physician) charges, and our team works with facility billing teams to coordinate claims for ambulatory surgery center (ASC) and hospital outpatient department (HOPD) encounters. Contact us to discuss your specific practice structure and billing needs at www.houseofoutsourcing.com.
Get a free assessment from our billing experts
